KIT FOR ISOLATION OF PLATELET-RICH PLASMA AND THE METHOD USING THE SAME

Abstract

Provided herein is a kit for isolation of platelet-rich plasma, comprising a first isolation tube and a second isolation tube. The first isolation tube comprises a first opening and a second opening, and the second isolation tube comprises a first portion, a second portion, and a filter; wherein the first portion has a third opening, the filter is disposed between the first portion and the second portion, the second opening has a diameter in a range of 1 to 5 mm and the filter has a pore size in a range of 1.5 to 4 μm.

Claims

1. A kit for isolation of platelet-rich plasma, comprising: a first isolation tube, comprising a first opening and a second opening, and a second isolation tube, comprising a first portion, a second portion, and a filter; wherein the first portion has a third opening, the filter is disposed between the first portion and the second portion, the second opening has a diameter in a range of 1 to 5 mm and the filter has a pore size in a range of 1.5 to 4 μm.

2. The kit of claim 1, wherein the ratio of the first portion and the second portion is between 45:55 to 35:65.

3. The kit of claim 1, wherein the first portion and the second portion are dismantlable.

4. The kit of claim 1, further comprising a first cap, a second cap, and a third cap to cover the first opening, the second opening, and the third opening respectively.

5. A method of isolation of platelet-rich plasma, comprising: providing the kit of claim 1; disposing a blood sample in the first isolation tube through the first opening; centrifuging the first isolation tube to separate a bottom layer, a buffy coat layer, and an upper layer; discarding the bottom layer from the second opening; transferring the buffy coat and the top layer to the second isolation tube through the third opening; centrifuging the second isolation tube to collect the platelet-rich plasma in the second portion.

6. The method of claim 5, wherein the centrifugation is performed by 2,200 to 2,400 g.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the preferred embodiments shown.

[0010] In the drawings:

[0011] FIG. 1 shows the illustrative view of the kit according to the present disclosure; (A) first isolation tube; (B) second isolation tube.

[0012] FIG. 2 shows the number of platelets of PRPs isolated by the kit of the present disclosure, commercialized PRP kits, whole blood (WB), and conventional protocol PRP (CP-PRP).

[0013] FIG. 3 shows the concentration of the growth factor released from activated PRPs of all groups set forth in Table 1: (A) FGF-2, (B) TGF-β1; the same mark (a, b, c, d, or d) means no significant statistical difference, and significance levels were indicated as *(p<0.05), **(p<0.01), and ***(p<0.001).

DETAILED DESCRIPTION OF THE INVENTION

[0014] The following embodiments when read with the accompanying drawings are made to clearly exhibit the above-mentioned and other technical contents, features and effects of the present disclosure. Through the exposition by means of the specific embodiments, people would further understand the technical means and effects of the present disclosure adopted to achieve the above-indicated objectives. Moreover, as the contents disclosed herein can be readily understood and implemented by a person skilled in the art, all equivalent changes or modifications which do not depart from the concept of the present disclosure shall be encompassed by the appended claims.

[0015] Furthermore, the ordinals recited in the specification and the claims such as “first”, “second” and so on are intended only to describe the elements claimed and imply or represent neither that the claimed elements have any proceeding ordinals, nor the sequence between one claimed element and another claimed element or between steps of a manufacturing method. The use of these ordinals is merely to differentiate one claimed element having a certain designation from another claimed element having the same designation.

[0016] Furthermore, the terms recited in the specifications and the claims such as “on” are intended not only directly contact with the other element, but also intended indirectly contact with the other element.

[0017] Kit for Isolation of Platelet-Rich Plasma (PRP)

[0018] Please refer to FIGS. 1 and 2. The kit for isolation of PRP comprises a first isolation tube 100 and a second isolation tube 200. The first isolation tube 100 has a first opening 101 and a second opening 102. In a preferred embodiment, the diameter of the first opening 101 is larger than the diameter of the second opening 102. In a more preferred embodiment, the second opening 102 has a diameter in a range of 1 to 5 mm. A first cap 110 is disposed on the first opening 101 and a second cap 120 is disposed on the second opening 102. As shown in FIG. 1, the diameter of the first isolation tube 100 reduces in the portion near the second opening 102 and form a tip-shape accordingly.

[0019] The second isolation tube comprises 200 a first portion 210, a second portion 220, and a filter 230. The first portion 210 has a third opening 201. The first portion 210 and the second portion 220 connect to each other and the filter 230 is disposed between the first portion 210 and the second portion 220. The filter 230 has a pore size in a range of 1.5 to 4 μm. A third cap is disposed on the third opening. Hence in the present disclosure, the first, second, and third cap 110, 120, 240 would cover the first, second, and third opening 101, 102, 201 respectively.

[0020] In a particular embodiment, the ratio of the first portion 210 and the second portion 220 is between 45:55 to 35:65. In a preferred embodiment, the ratio of the first portion 210 and the second portion 220 is approximately 40:60.

[0021] In a particular embodiment, the length of the first isolation tube 100 and the second isolation tube 200 is between 10 to 20 cm.

[0022] In a particular embodiment, the first portion 100 and the second portion 200 are dismantlable. However, in another embodiment, the first portion 100 and the second portion 200 are in one piece.

Example 1 Preparation of Blood Sample and Isolation of Platelet-Rich Plasma (PRP)

[0023] A total volume of 500 ml of whole blood harvested from a swine by an internal jugular venipuncture supplemented with ACD-A anticoagulant (GBiosciences, USA). The blood sample was divided into eight groups to isolate PRP by different protocol, as disclosed in Table 1.

TABLE-US-00001 TABLE 1 Abbreviation of the isolated Group product Description Whole Blood WB The whole blood directly harvested from a donor Conventional protocol CP-PRP The whole blood was harvested from a donor and go one-round centrifugation by 1600 g force to turn whole blood into three layers. The top two layers were collected and the bottom layer was discarded. Tube inserted with 5 μm H5M Platelet-rich plasma was isolated according to the filter method disclosed herein, wherein the filter has a cut-off pore size of 5 μm. The second tube is placed in a centrifuge; and then the leukocytes are further filtered out by 2300 g force from the product. Tube inserted with 3 μm H3M Platelet-rich plasma was isolated according to the filter method disclosed herein, wherein the filter has a cut-off pore size of 3 μm. The second tube is placed in a centrifuge; and then the leukocytes are further filtered out by 2300 g force from the product. Tube inserted with 2 μm H2M Platelet-rich plasma was isolated according to the filter method disclosed herein, wherein the filter has a cut-off pore size of 2 μm. The second tube is placed in a centrifuge; and then the leukocytes are further filtered out by 2300 g force from the product. Commercial kit VB Commercialized PRP kit

[0024] PRP is isolated by a two-step process. Firstly, a blood sample is disposed in a first isolation tube through the first opening. The first centrifugation is performed to separate a bottom layer, a buffy coat layer, and an upper layer in the first isolation tube. The bottom layer is discarded from the second opening and then the buffy coat and the top layers are transferred to the second isolation tube through the third opening, i.e. are disposed in the first portion. The second centrifugation is performed to spin down the plasma in the second isolation tube. As a consequence, the plasma passes through the filter and the PRP is collected in the second portion, whereas the leukocyte is detained in the filter.

Example 2 Complete Blood Count

[0025] The concentration blood cells and platelets are counted in order to assess the efficiency of isolation. The isolation groups disclosed in Table 1 are respectively counted for the platelet, white blood cells, and red blood cells within by an automated veterinary hematology analyzer (IDEXX Procyte Dx) for complete blood count (CBC). The results are shown in FIG. 2 and Table 2.

[0026] Table 3 was to summarize the formulae for the counting and evaluation to all the blood cellular components.

[0027] Unless otherwise described, the experiment data in the present disclosure are presented as mean±S.D by using GraphPad Prism software 6. The data were analyzed by one-way ANOVA, followed by Tukey multiple comparison test with significance levels were indicated as *p<0.05, **p<0.01, and ***p<0.001.

[0028] As shown in FIG. 2, the platelet concentration of group CP-PRP and group WB (whole blood) were 239×10.sup.3/μl and 119×10.sup.3/μl, respectively; which was approximately 2-times rich. The platelet number for group H5M, group H3M, group H2M, and group VB are 8.5×10.sup.3/μl, 17.0×10.sup.3/μl, 22.0×10.sup.3/μl, and 13.0×10.sup.3/μl, respectively. Among these, the group H2M showed the highest platelet number. Although the platelet concentration of group CP-PRP and group WB was much higher than that of group H2M, however, in view of Table 2, the white blood cells (WBCs) yield in the CP-PRP is much higher than those in H2M, H3M, and H5M and thus the PRP collected in group CP-PRP is probable of causing the intensifying of the local inflammation. WB contained too much both in WBCs and red blood cells (RBCs) that may not only induce local inflammation but also slow down the healing process.

TABLE-US-00002 TABLE 2 Initial volume Final volume Volume Yield Platelet Yield RBC Yield WBC Yield PRP kits (ml) (ml) (VY %) (PY %) (RY %) (WY %) CP-PRP 30 15.65 ± 1.32  50.24 ± 4.40 100.90 ± 8.83  0.18 ± 0.03 27.83 ± 15.94 H5M 4 1.93 ± 0.09 48.13 ± 2.29 3.44 ± 0.16 0.05 ± 0.02 0 H3M 4 1.82 ± 0.09 45.39 ± 2.37 6.48 ± 0.34 0.01 ± 0.00 0 H2M 4 1.82 ± 0.09 45.39 ± 2.37 8.39 ± 0.44 0 0 Commercial Kit 10 3.833 ± 0.29  38.33 ± 1.44 4.19 ± 0.16 0 5.3

TABLE-US-00003 TABLE 3 [00001]$A.\mathrm{Volume}\mathrm{Yield}\left(\mathrm{VY}\%\right)=\frac{\mathrm{volume}\mathrm{of}\mathrm{product}\left(\mathrm{ml}\right)}{\mathrm{volume}\mathrm{of}\mathrm{WB}\mathrm{processed}\left(\mathrm{ml}\right)}\times 100$ [00002]$B.\mathrm{Platelet}\mathrm{Yield}\left(\mathrm{PY}\%\right)=\frac{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{product}\left(\mathrm{ml}\right)\times \\ \mathrm{Platelet}\mathrm{concentration}\mathrm{in}\mathrm{product}\\ \left(\times {10}^9\text{/}\mu L\right)\end{array}}{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{WB}\mathrm{collected}\left(\mathrm{ml}\right)\times \\ \mathrm{Platelet}\mathrm{concentration}\mathrm{in}\mathrm{WB}\\ \left(\times {10}^9\text{/}\mu L\right)\end{array}}\times 100$ [00003]$C.\mathrm{RBC}\mathrm{Yield}\left(\mathrm{RY}\%\right)=\frac{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{product}\left(\mathrm{ml}\right)\times \\ \mathrm{RBC}\mathrm{concentration}\mathrm{in}\mathrm{product}\left(\times {10}^9\text{/}L\right)\end{array}}{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{WB}\mathrm{collected}\left(\mathrm{ml}\right)\times \\ \mathrm{RBC}\mathrm{concentration}\mathrm{in}\mathrm{WB}\left(\times {10}^9\text{/}L\right)\end{array}}\times 100$ [00004]$D.\mathrm{WBC}\mathrm{Yield}\left(\mathrm{WY}\%\right)=\frac{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{product}\left(\mathrm{ml}\right)\times \\ \mathrm{WBC}\mathrm{concentration}\mathrm{in}\mathrm{product}\left(\times {10}^9\text{/}L\right)\end{array}}{\begin{array}{c}\mathrm{volume}\mathrm{of}\mathrm{WB}\mathrm{collected}\left(\mathrm{ml}\right)\times \\ \mathrm{WBC}\mathrm{concentration}\mathrm{in}\mathrm{WB}\left(\times {10}^9\text{/}L\right)\end{array}}\times 100$

[0029] Table 2 shows the summary of blood count and the concentration of isolated PRPs yielded. The groups according to the present disclosure, which employ the kit of the present disclosure, including groups H5M, H3M, and H2M collected relatively high final volume and volume yield of PRPs from the whole blood, than those of commercialized kits of group VB

[0030] The PRP in the groups according to the present disclosure were successfully and efficiently isolated because the filter is permeable only for the platelets and detain other cells.

[0031] The groups H2M, H3M, and H5M according to the present disclosure could effectively separate RBCs and WBCs from PRPs, especially for the H2M group. Moreover, the RBCs in groups H5M and H3M are reduced to 0.05% and 0.01%, respectively, which is significantly lower than the CP-PRP group (conventional protocol).

[0032] Accordingly, PRPs isolated by the kit according to the present disclosure (H2M, H3M, and H5M) yield better volume and platelet concentration, which implies that the kit and the method according to the present disclosure efficiently and successfully isolates the PRP from whole blood sample and only extremely low or even no erythrocyte and leukocyte is present in the final product.

Example 3 Growth Factor Quantification

[0033] The growth factors quantification of PRPs including fibroblast growth factor-2 (FGF-2) and tumor growth factor-beta-1 (TGF-β1) were quantified by using ELISA kits (Wuhan USCN Business. Co., Ltd., USA) according to the user instructions.

[0034] The growth factors quantification of the prepared PRPs were shown in FIG. 3. The concentration of growth factors, FGF-2, and TGFß-1 in the PRPs prepared from groups H2M, H3M, and H5M according to the present disclosure and CP group were all far above average. The concentrations of growth factors in PRPs prepared from the other commercialized kit were fluctuation very much.

[0035] As for the concentration of FGF-2 (FIG. 3(A)), the concentration in group H5M, group H3M, group H2M, and group CP were all higher than 750 pg/ml. The concentration in group VB was lower than 500 pg/ml.

[0036] As for the concentration of TGFß-1 (FIG. 3(B)), the concentration in group H5M, group H3M, group H2M, and group CP were all higher than 1750 pg/ml. The concentration in group VB was lower than 1500 pg/ml.

[0037] The results demonstrates that the concentrations of growth factors in group using the kit according to the present disclosure were relatively stable and far above average.

[0038] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only and can be implemented in combinations. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.